Labeling Suit Costs Johnson & Johnson $63 Million

By Admin
A tragic reaction to a widely used medication – Childrens Motrin manufactured by Johnson & Johnson – caused a child to develop toxic ep...

A tragic reaction to a widely used medication – Children’s Motrin manufactured by Johnson & Johnson – caused a child to develop toxic epidermal necrolysis, eventually losing her sight and most of her skin in 2003.

Now, a jury has awarded the Massachusetts teenager and her parents a sum of $63 million over claims that the New Jersey-based multinational failed to provide adequate warnings of potential side effects on the medication’s label.

The extremely rare condition is usually caused by a reaction to drugs. Symptoms first include a fever before severely affecting the mucous membranes, leading to peeling skin covering the entire body.

Mystery Illness - Toxic Epidermal Necrolysis

The Jury’s decision reached Wednesday was met with protests from J&J’s McNeil consumer healthcare division and a statement read, “We disagree with today's verdict and are considering additional legal options. The Reckis family has suffered a tragedy and we sympathize deeply with them.” However, the company believes the label contains sufficient information on side effects and the cause of the teen’s conditions “are very rare conditions, and the specific cause is difficult to ascertain.”

The settlement awarded $50 million to the victim and $6.5 million to each of her parents.


Featured Articles

Johnson & Johnson: Turning supplier spend into local support

Johnson & Johnson’s Global Supplier Diversity & Inclusion team is growing spending with social enterprises around the globe to expand its impact

Seasonal Affective Disorder’s impact on health & solutions

Dr Ravi Gill & Dr. Naomi Newman-Beinart discuss Seasonal Affective Disorder and its treatments, from vitamin D spray to light therapy

CGI teams up with Totalmobile for digital healthcare service

CGI is driving efficiency in healthcare. Hear from Helena Jochberger, at Manufacturing Digital LIVE, a free virtual event on Wednesday 6th December 2023

Deloitte: generative AI can improve access to healthcare

Technology & AI

Wipro & NVIDIA’s revolutionary healthcare uses generative AI


Healthtech platform CoverSelf extends seed round to US$8.2m

Technology & AI